Diabetes (type 2) - empagliflozin [ID641]: evaluation report
Contents:
01 - Pre-Meeting Briefing prepared by NICE
02 - Pre-Meeting Briefing - Appendices prepared by NICE
03 - Submission from the technology manufacturer - Boehringer Ingelheim
04 - NICE request to the manufacturer for clarification on their submission
05 - Manufacturer clarification response
06 - Consultee submission - ABCD and RCP
07 - Consultee submission – RCN
08 - Clinical expert personal perspective – Sathyapalan
09 - Clinical expert personal perspective – Winocour
10 - Patient expert personal perspective – Kuti
11 - Evidence Review Group report prepared by Warwick Evidence
12 - Evidence Review Group replacement page
13 - Evidence Review Group report addendum
14 - Manufacturer factual accuracy check of Evidence Review Group report
Please note: the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
Diabetes (type 2) - empagliflozin [ID641]: evaluation report
28 August 2014 (12.5 Mb 8 sec) |
This page was last updated: 27 August 2014